BACKGROUND: The purpose of this study was to investigate the anterior cingulate cortex (ACC) glutamate/glutamine (Glx) to creatine ratio (Glx/Cr) in two groups of children with Bipolar Disorder (BPD): those exhibiting manic symptoms requiring treatment and those being stably treated with the atypical antipsychotic risperidone. Atypical antipsychotics have been shown to increase serum glutamate levels and ACC Glx/Cr in subjects with schizophrenia. In this study, we hypothesized that the children with BPD in need of treatment would have lower Glx/Cr compared with the children with BPD being stably treated with risperidone. METHODS: Proton MR spectra were acquired, at 1.5 T, from the ACC of eighteen subjects with a DSM-IV diagnosis of BPD: ten (11.10+/-3.48 years; five female) were manic and not medicated with any antipsychotic and eight (10.88+/-2.99 years; one female) were medicated with the atypical antipsychotic risperidone. RESULTS: Children with BPD exhibiting manic symptoms requiring treatment had lower Glx/Cr than children with BPD being stably treated with the atypical antipsychotic risperidone. The children treated with risperidone also had significantly lower YMRS and CGI-Mania scores than the children not treated with risperidone. Both YMRS and CGI-Mania scores correlated negatively with ACC Glx/Cr levels. LIMITATIONS: The cross-sectional design, small sample size, the use of Glx rather than glutamate or glutamine and the use of Cr ratios rather than absolute concentrations are limitations of this study. CONCLUSIONS: Children with mania have lower Glx/Cr levels than children with BPD being stably treated with the atypical antipsychotic risperidone. Mania may be associated with reduced glutamate/glutamine levels in the ACC: other imaging studies have shown mania associated with hypometabolism in the ACC. These reductions in glutamate/glutamine may be increased following successful treatment with glutamatergic agents.
BACKGROUND: The purpose of this study was to investigate the anterior cingulate cortex (ACC) glutamate/glutamine (Glx) to creatine ratio (Glx/Cr) in two groups of children with Bipolar Disorder (BPD): those exhibiting manic symptoms requiring treatment and those being stably treated with the atypical antipsychotic risperidone. Atypical antipsychotics have been shown to increase serum glutamate levels and ACC Glx/Cr in subjects with schizophrenia. In this study, we hypothesized that the children with BPD in need of treatment would have lower Glx/Cr compared with the children with BPD being stably treated with risperidone. METHODS: Proton MR spectra were acquired, at 1.5 T, from the ACC of eighteen subjects with a DSM-IV diagnosis of BPD: ten (11.10+/-3.48 years; five female) were manic and not medicated with any antipsychotic and eight (10.88+/-2.99 years; one female) were medicated with the atypical antipsychotic risperidone. RESULTS:Children with BPD exhibiting manic symptoms requiring treatment had lower Glx/Cr than children with BPD being stably treated with the atypical antipsychotic risperidone. The children treated with risperidone also had significantly lower YMRS and CGI-Mania scores than the children not treated with risperidone. Both YMRS and CGI-Mania scores correlated negatively with ACC Glx/Cr levels. LIMITATIONS: The cross-sectional design, small sample size, the use of Glx rather than glutamate or glutamine and the use of Cr ratios rather than absolute concentrations are limitations of this study. CONCLUSIONS:Children with mania have lower Glx/Cr levels than children with BPD being stably treated with the atypical antipsychotic risperidone. Mania may be associated with reduced glutamate/glutamine levels in the ACC: other imaging studies have shown mania associated with hypometabolism in the ACC. These reductions in glutamate/glutamine may be increased following successful treatment with glutamatergic agents.
Authors: R Kikinis; M E Shenton; G Gerig; J Martin; M Anderson; D Metcalf; C R Guttmann; R W McCarley; W Lorensen; H Cline Journal: J Magn Reson Imaging Date: 1992 Nov-Dec Impact factor: 4.813
Authors: P F Renshaw; B Lafer; S M Babb; M Fava; A L Stoll; J D Christensen; C M Moore; D A Yurgelun-Todd; C M Bonello; S S Pillay; A J Rothschild; A A Nierenberg; J F Rosenbaum; B M Cohen Journal: Biol Psychiatry Date: 1997-04-15 Impact factor: 13.382
Authors: Erin M Miller; Francois Pomerleau; Peter Huettl; Greg A Gerhardt; Paul E A Glaser Journal: Psychopharmacology (Berl) Date: 2014-02-28 Impact factor: 4.530
Authors: Manpreet K Singh; Booil Jo; Nancy E Adleman; Meghan Howe; Layla Bararpour; Ryan G Kelley; Daniel Spielman; Kiki D Chang Journal: Psychiatry Res Date: 2013-09-09 Impact factor: 3.222
Authors: Xian-Feng Shi; Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Fiedler; Eun-Kee Jeong; Rebekah S Huber; Perry F Renshaw Journal: Bipolar Disord Date: 2012-07-20 Impact factor: 6.744
Authors: Janet Wozniak; Carter R Petty; Meghan Schreck; Alana Moses; Stephen V Faraone; Joseph Biederman Journal: J Psychiatr Res Date: 2011-06-17 Impact factor: 4.791
Authors: D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw Journal: AJNR Am J Neuroradiol Date: 2014-02-20 Impact factor: 3.825
Authors: Nick C Patel; Kim M Cecil; Stephen M Strakowski; Caleb M Adler; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2008-12 Impact factor: 2.576